The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Filter
Locations
Result types
Type of company
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
Lock keywords
Exclude keywords
Optional keywords
New York, United States
51-100 Employees
We are located in Guangzhou Science City, Guangdong province, China, which serves as a global center for high technology and innovation. Make genome editing easier is the goal of Ubigene. We are committed to providing the best gene-editing services and products to every customer who chooses us. Innovatively improved from CRISPR/Cas9 technology, CRISPR-U™ has greatly improved the efficiency of gene cutting and homologous recombination, thus improving the gene-editing efficiency by 10-20 times. Ubigene had optimized the microbial gene-editing vectors and process. It is an automated gene-editing strategy design system. Combining with 3000 cases of gene-editing data, bioinformatics and information technology, Ubigene created this system to benefit researchers who work on gene editing. This platform is based on self-developed UBI-001 near-haploid cell line and 2000+ KO cell bank.
+
Featured
iPSC and ESC gene editing service
... and ESC gene editing service ...
South San Francisco, United States
101-250 Employees
2020
Kim Drapkin has over 25 years of experience working with private and publicly traded biotechnology and pharmaceutical companies, including building and leading finance functions, raising capital, and leading strategic financial planning. Garrett brings more than 25 years of industry experience leading high-performing, cross-functional teams at global biopharmaceutical companies to advance the development and life-cycle management of pipeline and approved therapies. Karsen served as the chief executive officer of the Celgene Cellular Therapeutics division of Celgene Corporation and as executive vice president and chief operations officer of Celgene Corporation. Kim Drapkin is the Chief Executive Officer of Graphite Bio. Kristen Hege is a renowned physician-scientist and a pioneer in advancing cell therapies through clinical development to regulatory approval. Joe Jimenez is the former chief executive officer of Novartis, one of the world’s leading pharmaceutical companies. Matthew Porteus is an academic founder of Graphite Bio and a pioneer in the field of gene editing. Carlo Rizzuto is a seasoned biopharmaceutical business executive and investor with over 2 decades of diverse leadership experience.
+
Featured
We’re a gene editing company committed to cures
... Graphite Bio is a next-generation gene-editing company driven to discover and develop cures for patients living with serious diseases. ...
Zurich, Switzerland
11-50 Employees
2018
A Human Artificial Chromosome (HAC) is a multi-gene delivery platform for genetically engineering human cells. This platform can accept, deliver and express genes with multiple therapeutic or bio-production functions including, but not limited to: biologics, viral vectors, enzymes, small and large therapeutic RNAs, CRISPR/Cas proteins, and guide RNAs, drug-producing gene clusters, therapeutic proteins, real-time responsive biosensors, and bio-polymer proteins. To meet the technical requirements of implementing such a complex gene therapy, at Centaura we are working on developing a novel approach to massive gene editing—the Human Artificial Chromosome.
+
Featured
Game changer in human gene editing
... Game changer in human gene editing ...
Cambridge, United Kingdom
1-10 Employees
Our vision is a future where cell & gene therapies are safer, more efficient, and affordable for patients. We are building partnerships with scientific leaders and world-renowned organisations. INDUCE-seq™ is a game changing technology for the characterisation of genome breaks in cell & gene therapy applications. Our team operates at the intersection of biology, bioinformatics and data science. Come and join our dynamic and growing team to share in our vision of delivering on the promise of gene editing. With an extensive background leading quality assurance in….
+
Featured
Delivering on the promise of gene editing
... Our platform accelerates the characterisation of novel gene editing technologies to unlock the next wave of cell & gene therapies. ...
Emeryville, United States
51-100 Employees
2018
At Metagenomi, we are creating potentially curative therapeutics using our metagenomics-powered genome editing toolbox. Metagenomi ventures out into less-trodden natural environments to source undiscovered genetic material—and then brings it into their lab to sequence and engineer into genetic medicines. We are taking a stepwise approach deploying our genome editing toolbox to develop potentially curative therapies for patients. Metagenomi’s portfolio of programs aims to match the optimal genome editing tool for each indication and capture an ever-growing set of translational insights that inform and accelerate future programs.
+
Featured
Curative Gene Editing Forged From Nature | Metagenomi
... Metagenomi is transforming novel gene editing tools, mined from the world’s natural microbial environment, into life-saving genetic medicines. ...
Keystone, United States
1-10 Employees
2015
CRISPRcon is a unique forum bringing diverse voices together to discuss the future of CRISPR and gene editing technologies across applications in agriculture, health, conservation, and more. CRISPRcon sparks curiosity, builds understanding, and highlights societal histories and other context relevant to decisions on gene editing technologies. CRISPRcon is a program of the Keystone Policy Center, a nonprofit founded in 1975 to help diverse leaders reach higher common ground on pressing issues in agriculture, natural resources, energy, education, and health. Finally, thanks to all CRISPRcon participants who have contributed their insights though polling, small group discussion, and feedback surveys and who have helped us question, learn, and improve our events. The CRISPRcon team is excited that these online opportunities will offer more people the chance to participate in critical discussions, hear different perspectives, and share their views on the risks, benefits, and ethics of new and emerging genetic technologies. CRISPRcon creates a unique forum in which a broad selection of diverse voices come together to discuss the future of CRISPR and related gene editing technologies across a variety of applications in agriculture, health, conservation and more. CRISPRcon welcomes sponsorship from organizations, businesses, foundations, universities, NGOs, and others interested in supporting the CRISPRcon mission to create a unique forum of diverse perspectives on gene editing across a variety of applications. Thank you to the following individuals who have helped support the CRISPRcon mission by inspiring ideas, identifying possible speakers and discussion topics, and sparking dialogue about these critical issues.
+
Featured
the future of gene editing
... CRISPRcon - Conversations on Science, Society and the Future of Gene Editing ...
General San Martín, Argentina
1-10 Employees
First, using computational tools we study which genes are responsible for a desirable trait in order to develop the most promising plants. Then, we edit the genes of interest using proprietary CRISPR-Cas9 tools creating Non-GMO plants that will grow in controlled environments reaching their highest genetic potential. Finally, we validate the new gene-edited plants with improved traits in field conditions. The data obtained is used to feed and reinforce our technology platform. © Copyright Calice Biotech 2023 | Todos los derechos reservados.
+
Featured
Calice – Plant Biotech for a better world
... In Cálice Biotech we developed a technology platform that combines data science, bioinformatics, and gene editing tools to produce plants that are more productive, resistant and environment-friendly. ...
Herzliya, Israel
2017
ImmunoBrain Checkpoint Awarded $5 Million US NIA Grant for Phase 1b Alzheimer’s Disease. Advaxis and Biosight Announce Entry into Definitive Merger Agreement. LogicBio Announces First Patient Dosed in Groundbreaking Phase 1/2 SUNRISE Clinical Trial.
+
Featured
Home | SBIJI
... Cures for serious, early-onset rare diseases by combining the best of gene therapy and gene editing ...
Ann Arbor, United States
1-10 Employees
2015
Our mission is to discover the best-in-class therapeutic biologics through the novel animals and technology platforms. Our mission is to discover the best-in-class therapeutics through the novel platforms. The company is dedicated to the development of novel transgenic rabbits as discovery platforms and bioreactors to produce therapeutic biologics such as monoclonal antibodies. ATGC also provides services to the biomedical community using our proprietary technology platforms and unique animals. ATGC also strives to serve the biomedical community with products and technologies using our unique platforms.
+
Featured
High knock-in rate gene editing enzyme miCas9
... High knock-in rate gene editing enzyme ...
Stevenage, United Kingdom
11-50 Employees
Laverock's differentiated technology allows generation of products with improved efficacy, safety and accessibility, overcoming many of the limitations with existing approaches. These next-generation products are able to deliver directed, responsive activities ensuring favourable on- and off-target profiles.
+
Featured
Programmable Cell Therapies, CRISPR Gene Editing | Laverock Therapeutics
... Laverock Therapeutics’ mission is to engineer next-generation programmable cell therapies using advanced RNAi gene editing technology & ...
Technologies which have been searched by others and may be interesting for you:
Some interesting numbers and facts about the results you have just received for Gene Editing
| Country with most fitting companies | United States |
| Amount of fitting manufacturers | 118 |
| Amount of suitable service providers | 84 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 2015 |
| Youngest suiting company | 2020 |
Gene editing is a sophisticated biotechnological technique that allows scientists to precisely alter, remove, or add specific segments of DNA within an organism's genome. This method employs engineered nucleases, commonly referred to as "molecular scissors," which initiate targeted modifications by creating breaks in the DNA strands at specific locations. The cell's natural repair mechanisms then introduce the desired changes as they mend these breaks. The most notable advancement in this field is the CRISPR-Cas9 system, which has revolutionized gene editing for its simplicity, efficiency, and versatility. The impact of gene editing extends across various domains, including agriculture, where it enables the development of crops with enhanced yield, nutritional value, and resistance to pests and diseases. In medicine, it holds the promise of curing genetic disorders by correcting faulty genes directly within patients' cells, offering potential treatments for conditions that were previously deemed untreatable. Furthermore, gene editing contributes to fundamental scientific research by facilitating the study of gene functions and interactions, thereby advancing our understanding of complex biological processes. Despite its vast potential, gene editing also raises ethical and safety concerns, particularly regarding its use in human embryos and the potential for unintended consequences, necessitating ongoing dialogue and regulation within the scientific community.
1. Precision
Gene editing offers unparalleled precision in modifying organisms' DNA. Unlike traditional genetic engineering methods, which can introduce random gene insertions, gene editing technologies like CRISPR allow scientists to target and edit specific gene sequences. This accuracy minimizes unintended consequences and enhances the reliability of genetic modifications.
2. Speed
The process of gene editing is significantly faster than alternative genetic modification techniques. Traditional methods can take years to achieve desired genetic changes, whereas gene editing can produce results in a matter of months. This rapid turnaround is crucial for timely advancements in medical research, agriculture, and environmental conservation.
3. Cost-effectiveness
Gene editing technologies are more cost-effective compared to older genetic engineering methods. The reduced cost is primarily due to the simplicity and efficiency of the gene editing process, which requires fewer resources and less time. This affordability allows for broader access to gene editing applications, making cutting-edge research and development more accessible to smaller laboratories and institutions.
4. Versatility
Gene editing can be applied across various species and for numerous purposes, from correcting genetic disorders in humans to enhancing crop resilience. This versatility showcases gene editing's potential to address a wide range of scientific, medical, and agricultural challenges, making it a universal tool in the pursuit of genetic improvement and innovation.
While evaluating the different suppliers make sure to check the following criteria:
1. Expertise and Experience
Ensure the supplier has a proven track record in gene editing, with specific experience in the relevant technology, such as CRISPR, TALEN, or ZFN.
2. Quality Control Measures
Check for rigorous quality control protocols and the ability to provide detailed documentation of their processes and outcomes.
3. Customization Abilities
Assess the supplier's capacity to customize their services to fit unique project requirements, including specific target genes and cell types.
4. Regulatory Compliance
Verify that the supplier adheres to all relevant regulatory standards and ethical guidelines for gene editing research.
5. Support and Communication
Look for responsive customer support and clear, open communication channels to facilitate the smooth progression of projects.
6. Turnaround Time and Scalability
Consider the supplier's ability to meet project timelines and scale operations to accommodate the project size and complexity.
7. Cost-Effectiveness
Evaluate the overall value offered by the supplier, balancing cost against quality, expertise, and the range of services provided.
Gene editing technologies, particularly CRISPR and TALENs, have unlocked new possibilities across multiple sectors. In agriculture, businesses leverage gene editing for crop improvement, focusing on enhancing nutritional value, yield, and resistance to pests and diseases. This application not only boosts food security but also reduces reliance on chemical pesticides, aligning with sustainable farming practices. In the pharmaceutical industry, gene editing plays a critical role in drug discovery and development. By manipulating genes in disease models, researchers can better understand disease mechanisms, leading to the identification of new drug targets. This accelerates the development of more effective and personalized medications, offering hope for patients with genetic disorders and complex diseases. The biotechnology sector sees gene editing as a tool for industrial enzyme engineering. By modifying the genes of microorganisms, companies can produce enzymes with improved efficiency or novel functions. These enhanced enzymes are crucial for various applications, including biofuel production, waste management, and the manufacturing of biodegradable plastics, driving innovation and sustainability in industrial processes. Lastly, gene editing is pivotal in animal genetics, where it is used to improve livestock traits such as growth rates, disease resistance, and meat quality. This not only improves the profitability and sustainability of animal farming but also addresses ethical concerns by potentially reducing the need for antibiotics and growth hormones.
Gene editing, a revolutionary technique that enables precise modifications within an organism's DNA, has rapidly advanced, currently situating at a Technology Readiness Level (TRL) of 4 to 5. This classification reflects its progression from basic research to technology validations in controlled environments. The primary technical reason for this TRL positioning is the successful demonstration of gene editing's efficacy and reproducibility in laboratory settings, particularly through CRISPR-Cas9, which has shown unparalleled precision in targeting and editing specific genetic sequences. However, its transition to higher TRLs is moderated by challenges such as ensuring the ethical application of gene editing in humans, accurately predicting off-target effects, and developing robust delivery mechanisms for therapeutic uses. Despite these obstacles, the technology has seen significant achievements, including the treatment of genetic disorders in animal models and early-stage clinical trials in humans, indicating a solid foundation for future development and application. The meticulous approach to scaling gene editing technologies from theoretical frameworks to practical applications underscores the cautious yet optimistic advancement within this field, reflecting its current TRL status.
Short-Term In the immediate future, gene editing is poised to undergo significant advancements, particularly in the realm of CRISPR technology. Researchers are expected to unveil more precise editing techniques, reducing off-target effects and increasing safety profiles. This phase will also see the development of more versatile CRISPR systems capable of targeting a broader range of genetic sequences, thereby expanding the potential for therapeutic applications in genetic diseases. Mid-Term Over the next few years, the focus will shift towards optimizing delivery mechanisms for gene-editing tools. This phase will witness the integration of nanotechnology and viral vectors to enhance the efficiency and specificity of gene editing in complex tissues and organs. Such advancements will pave the way for treating a wider array of diseases, including those considered intractable today. Additionally, regulatory frameworks around the world will begin to adapt, allowing for more clinical trials and applications of gene editing in human medicine. Long-Term Looking further ahead, gene editing will likely become a cornerstone in preventive medicine. The long-term focus will be on heritable gene editing, with the potential to eradicate genetic diseases before birth. This era will also explore the ethical, social, and legal implications of gene editing, ensuring that advancements are implemented responsibly. Moreover, agricultural and environmental applications will mature, using gene editing to address food security and biodiversity conservation, marking a paradigm shift in how humanity interacts with the natural world.
